Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica

Journal of Rheumatology

Volumn 33, Issue 4, 2006, Pages 703-708

  Boiardi, Luigi ^a   Casali, Bruno ^b   Farnetti, Enrico ^b   Pipitone, Nicolò ^a   Nicoli, Davide ^c   Cantini, Fabrizio ^d   Macchioni, Pierluigi ^a   Bajocchi, Gianluigi ^a   Catanoso, Maria Grazia ^a   Pulsatelli, Lia ^e   Consonni, Dario ^f   Salvarani, Carlo ^a  

^a Servizio di Reumatologia   (Italy)

^b Laboratorio di Biologia Molecolare   (Italy)

^c Laboratorio di Biologia Molecolare   (Italy)

^d MISERICORDIA E DOLCE HOSPITAL   (Italy)

^e Laboratorio di Immunologia e Genetica   (Italy)

^f PARKINSON INSTITUTE   (Italy)

Author keywords

Interleukin 6 polymorphism; Polymyalgia rheumatica; Relapse recurrence; Serum interleukin 6 levels

Indexed keywords

ACUTE PHASE PROTEIN; INTERLEUKIN 6;

AGED; ALLELE; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; RHEUMATIC POLYMYALGIA; RISK ASSESSMENT;

AGED; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; POLYMORPHISM, GENETIC; POLYMYALGIA RHEUMATICA; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RECURRENCE;

EID: 33645800794     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-68.
2. Corrigall VM, Dolan AL, Dasgupta B, Panayi GS. The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal. Br J Rheumatol 1997;36:976-80.
3. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990;29:456-8.
4. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
5. Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;159:577-84.
6. Salvarani C, Cantini F, Niccoli L, et al. Acute-phase response reactants and the risk of developing relapse/recurrence in polymyalgia rheumatica: a prospective follow up study. Arthritis Rheum 2005;53:33-8.
7. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
8. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984;13:322-8.
9. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Licastro F, Grimaldi LM, Bonafe M, et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003;24:921-6.
11. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001;22:2243-52.
12. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:2066-71.
13. Flex A, Gaetani E, Pola R, et al. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vasc Endovasc Surg 2002;24:264-8.
14. DeMichele A, Martin AM, Mick R, et al. Interleukin-6 -174G->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003;63:8051-6.
15. Vozarova B, Fernandez-Real JM, Knowler WC, et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with typc-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 2003;112:409-13.
16. Ferrari SL, Garnero P, Emond S, Montgomery H, Humphries SE, Greenspan SL. A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women. Arthritis Rheum 2001;44:196-201.
17. Schluter B, Raufhake C, Erren M, et al. Effect of the interlcukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002;30:32-7.
18. Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. 1L-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002;20:179-84.
19. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
20. Salvarani C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia. Italy. Clin Exp Rheumatol 1987;5:205-15.
21. Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica: duration of therapy and long-term outcome. Am J Med 1985;79:309-15.
22. Andersson R, Malmvall B-E, Bengtsson B-A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986;220:465-9.
23. Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 2001;30:260-7.
24. Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52:847-50.
25. Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ. HLA-DRB1 alleles in polymyalgiu rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994;37:514-20.
26. Haworth S, Ridgewuy I., Stewart I, Dyer PA, Pepper L, Ollier W. Polymyalgia rheumatica is associated with both HLA-DRB1*0401 and DRB 1*0404. Br J Rheumatol 1996;35:632-5.
27. Salvarani C, Boiardi L, Mantovani V, et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis 1999;58:303-8.
28. Salvarani C, Casali B, Boiardi L, et al. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2000;27:1215-21.
29. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10-year study. J Rheumatol 1999;26:1326-32.
30. Amoli MM, Shelley E, Mattey DL, et al. Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica. J Rheumatol 2002;29:502-4.
31. Schreiber S, Buyse M. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin Rheumatol 1995;14:315-8.
32. Jones KG, Brull DJ, Brown LC, et al. Interleukin-6 (1L-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001;103:2260-5.
33. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>e and -572g>e promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001;21:1458-63.
34. Kilpinen S, Hulkkonen J, Wang XY, Hurme M. The promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults. Eur Cytokine Netw 2001;12:62-8.
35. Rea IM, Ross OA, Armstrong M, et al. Interleukin-6-gene C/G 174 polymorphism in nonagenarian und octogenarian subjects in the BELFAST study. Reciprocal effects on IL-6, soluble IL-6 receptor and for IL-10 in serum and monocyte supernatants. Mech Ageing Dev 2003;124:555-61.
36. Bennermo M, Held C, Green F, et al. Prognostic value of plasma interleukin-6 concentrations and the -174 G > C and -372 G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 2004;174:157-63.
37. Kelberman D, Hawe E, Luong LA, et al. HIFMECH study group. Effect of interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. Thromh Haemost 2004;92:1122-8.
38. Basso F, Lowe GD, Rumley A, McMahon AD, Humphries SE. Interleukin-6 -I74G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002;22:599-604.
39. Burzotta F, Iacoviello L, Di Castelnuovo A, et al. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalisation after surgical coronary revascularization. Am J Cardiol 2001;88:1125-8.
40. Trevelyan J, Brull DJ, Needham EW, Montgomery HE, Morris A, Mattu RK. Effect of enalapril and losartun on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting und their interaction with polymorphisms in the interleukin-6 gene. Am J Cardiol 2004;94:564-9.
41. Bonale M, Olivieri F, Cavallone L, et al. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001;31:2357-61.